CDKN2A and astrocytoma (excluding glioblastoma): In the “cIMPACT-NOW” published in 2020, it was recommended that astrocytomas containing CDKN2A/B HD be considered WHO grade IV (2016) astrocytomas even if there is no microvascular proliferation (MVP) or necrosis (7).